Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel (albumin-bound) + Carboplatin in Recurrent Ovarian Cancer
NCT04661696Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Dec 2020
- Primary completion
- Feb 2024
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nab-paclitaxel in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
nab-paclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04661696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04661696.